{"id":9846,"date":"2021-05-17T10:16:57","date_gmt":"2021-05-17T17:16:57","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9846"},"modified":"2021-05-18T10:17:40","modified_gmt":"2021-05-18T17:17:40","slug":"seroconversion-rates-following-covid-19-vaccination-amongst-patients-with-malignant-disease-the-impact-of-diagnosis-and-cancer-directed-therapies","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/seroconversion-rates-following-covid-19-vaccination-amongst-patients-with-malignant-disease-the-impact-of-diagnosis-and-cancer-directed-therapies\/","title":{"rendered":"Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Among patients with cancer (n = 201) who were fully vaccinated with the Pfizer-BioNTech, Moderna, or Johnson &amp; Johnson\/Janssen vaccines, the majority (94%) showed seroconversion for anti-spike protein IgG. Lower seroconversion frequencies were observed for patients with <\/span><span style=\"font-weight: 400\">hematological malignancies (85%), particularly recipients of anti-CD20 therapies (70%) and stem cell transplantation (74%), compared to patients with solid organ tumors (98%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) also had high seroconversion. Overall, IgG titers were higher among those who received mRNA vaccines.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Thakkar et al.\u00a0(May 14, 2021). Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.07.21256824\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.07.21256824<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Among patients with cancer (n = 201) who were fully vaccinated with the Pfizer-BioNTech, Moderna, or Johnson &amp; Johnson\/Janssen vaccines, the majority (94%) showed seroconversion for anti-spike protein IgG. Lower seroconversion frequencies were observed for patients with hematological malignancies (85%), particularly recipients of anti-CD20 therapies (70%) and stem cell transplantation (74%), compared&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/seroconversion-rates-following-covid-19-vaccination-amongst-patients-with-malignant-disease-the-impact-of-diagnosis-and-cancer-directed-therapies\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[130,142],"topic":[31],"class_list":["post-9846","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-cancer","tag-vaccine","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9846"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9846\/revisions"}],"predecessor-version":[{"id":9847,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9846\/revisions\/9847"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9846"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}